Galderma Group AG (GALD) AI Stock Analysis

Top Page

Galderma Group AG

(Six Swiss:GALD)

Select Model

Rating:66Neutral

Price Target:CHF 171.00▼(-11.33% Downside)

Action:reiterated

Date:08/06/26

The score is driven primarily by improving financial performance (profitability and cash flow rebound plus materially lower leverage) and a supportive uptrend in the technicals. These positives are tempered by a demanding valuation (high P/E and minimal dividend yield) and some uncertainty around the consistency of revenue growth and cash-flow durability given prior volatility.

Positive Factors

High margins and profitabilityConsistently high gross margins and the rise in EBIT margin indicate stronger operating economics and improved profitability. If maintained, this combination can support reinvestment, absorb operating costs, and provide a more durable earnings base across the company’s dermatology segments.

Negative Factors

Uneven revenue growthThe decline in 2025 revenue despite sharply improved earnings shows that top-line momentum has not yet been consistently sustained. Uneven growth can make planning and investment returns less predictable, particularly across Galderma’s multiple product and channel businesses.

Galderma Group AG (GALD) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 44.97B
Dividend Yield: 0.18%
Average Volume (3M): 590.56K
Price to Earnings (P/E): 63.9
Beta (1Y): 0.89
Revenue Growth: 15.78%
EPS Growth: 111.61%
Country: Switzerland
Employees: 7,676
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Galderma Group AG Business Overview & Revenue Model

Company Description

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It...

How the Company Makes Money

Galderma makes money primarily by selling dermatology products across three main business areas: (1) Injectable Aesthetics: revenue from sales of aesthetic injectables used in-office by trained healthcare professionals (e.g., dermal fillers and other...

Galderma Group AG Financial Statement Overview

Summary

Strong turnaround: revenue meaningfully higher vs. 2021, consistently high gross margins (~67–70%), and a clear improvement in profitability with net income moving from losses (2021–2023) to solid profits (2024–2025) and EBIT margin rising to ~16.4% (2025). Balance sheet risk has de-rated with debt-to-equity falling to ~0.34–0.35x (2024–2025), and 2025 free cash flow improved sharply (~1.03B). Main caution: 2025 revenue dipped vs. 2024 and historical cash flow was volatile, so durability and top-line consistency remain key watch items.

Income Statement

76Positive

Balance Sheet

73Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.85B	5.24B	4.89B	4.29B	3.88B	3.42B
Gross Profit	3.92B	3.61B	3.40B	2.99B	2.65B	2.38B
EBITDA	1.33B	1.21B	1.03B	851.00M	633.04M	524.25M
Net Income	856.98M	642.16M	254.35M	-56.23M	-101.72M	-154.27M
Balance Sheet
Total Assets	13.56B	13.39B	12.62B	12.26B	12.42B	12.53B
Cash, Cash Equivalents and Short-Term Investments	841.26M	780.00M	457.00M	361.53M	234.18M	286.17M
Total Debt	2.70B	2.75B	2.76B	4.83B	5.66B	5.67B
Total Liabilities	5.33B	5.24B	4.83B	6.98B	7.95B	7.99B
Stockholders Equity	8.24B	8.15B	7.79B	5.28B	4.47B	4.53B
Cash Flow
Free Cash Flow	1.03B	1.03B	213.00M	43.35M	-49.77M	67.69M
Operating Cash Flow	1.16B	1.19B	488.00M	165.00M	114.93M	195.66M
Investing Cash Flow	-138.57M	-154.00M	-287.10M	-174.00M	-76.21M	-533.40M
Financing Cash Flow	-640.14M	-728.00M	-51.08M	142.00M	-74.45M	317.14M

Galderma Group AG Technical Analysis

Technical Analysis SentimentPositive

Last Price192.85

Price Trends

50DMA167.62Positive

100DMA171.32Positive

200DMA162.77Positive

Market Momentum

MACD6.96Negative

RSI73.38Negative

STOCH78.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:GALD, the sentiment is Positive. The current price of 192.85 is above the 20-day moving average (MA) of 175.65, above the 50-day MA of 167.62, and above the 200-day MA of 162.77, indicating a bullish trend. The MACD of 6.96 indicates Negative momentum. The RSI at 73.38 is Negative, neither overbought nor oversold. The STOCH value of 78.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:GALD.

Galderma Group AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

CH:GALD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CH:RO	75Outperform	CHF 321.78B	26.26	―	2.63%	-1.06%	30.86%
CH:NOVN	71Outperform	CHF 244.89B	31.19	―	2.77%	-4.48%	-33.14%
CH:SDZ	67Neutral	CHF 36.25B	67.02	7.04%	0.97%	0.81%	165.32%
CH:GALD	66Neutral	CHF 44.97B	63.88	―	0.18%	15.78%	111.61%
CH:GALE	66Neutral	CHF 4.38B	27.57	―	2.84%	6.48%	-17.25%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
CH:DOCM	55Neutral	CHF 773.38M	-9.70	―	―	―	―

* General Sector Average

Performance Comparison

CH:GALD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:GALD	Galderma Group AG	192.85	41.68	27.57%
CH:DOCM	DocMorris AG	15.32	10.04	189.88%
CH:NOVN	Novartis	133.78	37.22	38.54%
CH:SDZ	Sandoz Group Ltd	82.38	27.68	50.62%
CH:GALE	Galenica AG	87.95	3.61	4.28%
CH:RO	Roche Holding Ltd	411.20	147.82	56.12%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 06, 2026

Galderma Group AG AI Stock Analysis

Top Page